With billions on the line between pharma giants Johnson & Johnson and Pfizer, an appeals panel upheld a decision to invalidate a key Remicade patent. In a judgment entered Tuesday, the United States ...
Johnson & Johnson's big-selling Remicade has held most of its ground against biosimilar competition, thanks in part to some aggressive payer contracts that rivals—including Pfizer—have called into ...
The global remicade biosimilar market is projected to expand significantly between 2025 and 2035, with a market size growing from USD 2.32 billion in 2025 to USD 4.01 billion in 2035, at a robust ...
Pfizer Inc. filed suit against Johnson & Johnson, alleging J&J thwarted competition to its arthritis therapy Remicade, in a case that could shatter arrangements pharmaceutical companies make with ...
Pfizer is suing Johnson & Johnson, alleging that it induced US health insurers to help it block biosimilar competition to its blockbuster Remicade. Pfizer's Inflectra was the first monoclonal antibody ...
Oct 17 (Reuters) - Pfizer Inc said on Monday it will begin shipping its biosimilar version of Johnson & Johnson's blockbuster rheumatoid arthritis drug Remicade in late November at a 15 percent ...
(Reuters) - U.S. Food and Drug Administration staff members on Friday said Celltrion Inc's biosimilar form of Johnson & Johnson's Remicade arthritis drug appeared "highly similar" to the widely used ...
Pfizer Inc.PFE1.36%increase; green up pointing triangle filed suit against Johnson & Johnson JNJ 2.02%increase; green up pointing triangle, alleging J&J thwarted competition to its arthritis therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results